| __timestamp | Bristol-Myers Squibb Company | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3932000000 | 22732000 |
| Thursday, January 1, 2015 | 3909000000 | 29245000 |
| Friday, January 1, 2016 | 4946000000 | 33206000 |
| Sunday, January 1, 2017 | 6066000000 | 31152000 |
| Monday, January 1, 2018 | 6547000000 | 10136000 |
| Tuesday, January 1, 2019 | 8078000000 | 45546000 |
| Wednesday, January 1, 2020 | 11773000000 | 43367000 |
| Friday, January 1, 2021 | 9940000000 | 81413000 |
| Saturday, January 1, 2022 | 10137000000 | 139304000 |
| Sunday, January 1, 2023 | 10693000000 | 192361000 |
| Monday, January 1, 2024 | 11949000000 | 159417000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical landscape, understanding cost dynamics is crucial. Bristol-Myers Squibb Company, a titan in the industry, has seen its cost of revenue soar by approximately 172% from 2014 to 2023. This growth reflects its expansive operations and strategic investments. In contrast, Halozyme Therapeutics, Inc., a nimble player, has experienced a staggering 747% increase in the same period, albeit from a much smaller base. This sharp rise underscores its aggressive growth strategy and increasing market presence.
From 2014 to 2023, Bristol-Myers Squibb's cost of revenue consistently climbed, peaking in 2020. Meanwhile, Halozyme's costs, though significantly lower, have shown a remarkable upward trajectory, particularly from 2020 onwards. This divergence highlights the varied strategies and market positions of these two companies, offering a fascinating glimpse into the pharmaceutical industry's financial dynamics.
Cost Insights: Breaking Down Novartis AG and Bristol-Myers Squibb Company's Expenses
Cost of Revenue Comparison: Pfizer Inc. vs Bristol-Myers Squibb Company
Cost of Revenue Trends: Sanofi vs Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Bristol-Myers Squibb Company and GSK plc's Expenses
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and United Therapeutics Corporation
Cost of Revenue Comparison: Bristol-Myers Squibb Company vs Intra-Cellular Therapies, Inc.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Ionis Pharmaceuticals, Inc.
Catalent, Inc. vs Halozyme Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Cost of Revenue Trends: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and HUTCHMED (China) Limited
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Agios Pharmaceuticals, Inc.'s Expenses